Blog
In vivo CAR-T Insights Series (1) — What is In vivo CAR-T?
Release Time：
2025-11-13 14:14
What is In vivo CAR-T? How does it differ from traditional ex vivo CAR-T?
Traditional ex vivo CAR-T workflow: Collect patient’s T cells →Genetically modify them outside the body → Infuse them back into the patient.
While this approach has shown remarkable clinical success, it involves complex manufacturing, high costs, and long turnaround times.
In Vivo CAR-T — a new paradigm:
Instead of modifying T cells in a lab, in vivo CAR-T delivers genetic instructions directly inside the patient’s body, turning their own T cells into CAR-T cells on-site.
Key advantages:
1. Streamlined process – No cell collection or external manufacturing.
2. Lower costs – Eliminates expensive cell culture facilities.
3. Scalable – Potential for broader patient accessibility.
Challenges to address:
Delivery efficiency – Getting genetic material precisely to T cells.
Specificity – Avoiding off-target cell modification.
Safety – Minimizing immune-related toxicities.
Levostar’s in vivo CAR-T solutions
From mRNA plasmid design to LNP formulation, Levostar provides complete solutions for in vivo CAR-T research.
Our Ab-LNP technology enables targeted delivery — from ready-to-use standard products (e.g., LNP-CD3/5/8) to fully customized antibody conjugation services.
Let’s accelerate the future of cell therapy — directly inside the body.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898